Search

Your search keyword '"González-Barcala, Francisco-Javier"' showing total 509 results
Start Over Author "González-Barcala, Francisco-Javier"
509 results on '"González-Barcala, Francisco-Javier"'

5. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

Author

Valverde-Monge, Marcela, Sánchez-Carrasco, Patricia, Betancor, Diana, Barroso, Blanca, Rodrigo-Muñoz, José Manuel, Mahillo-Fernández, Ignacio, Arismendi, Ebymar, Bobolea, Irina, Cárdaba, Blanca, Cruz, María Jesús, Del Pozo, Victoria, Domínguez-Ortega, Javier, González-Barcala, Francisco Javier, Olaguibel, José María, Luna-Porta, Juan Alberto, Martínez-Rivera, Carlos, Mullol, Joaquim, Muñoz, Xavier, Peleteiro-Pedraza, Lorena, Picado Valles, Cesar, Plaza, Vicente, Quirce, Santiago, Rial, Manuel Jorge, Soto-Retes, Lorena, Valero, Antonio, and Sastre, Joaquín

Published
2024
Full Text
View/download PDF

6. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

Author

Romero-Mesones, Christian, Cruz, Maria-Jesus, Alobid, Isam, Barroso, Blanca, Arismendi, Ebymar, Barranco, Pilar, Betancor, Diana, Bobolea, Irina, Cárdaba, Blanca, Curto, Elena, Domenech, Gemma, Domínguez-Ortega, Javier, Espejo, David, González-Barcala, Francisco-Javier, Luna-Porta, Juan-Alberto, Martínez-Rivera, Carlos, Méndez-Brea, Paula, Mullol, Joaquim, Olaguibel, José-María, Picado, Cesar, Plaza, Vicente, del Pozo, Victoria, Quirce, Santiago, Rial, Manuel-Jorge, Rodrigo-Muñoz, José-María, Sastre, Joaquin, Serrano, Sandra, Soto-Retes, Lorena, Valero, Antonio, Valverde-Monge, Marcela, and Munoz, Xavier

Published
2023
Full Text
View/download PDF

10. Estudio de prevalencia de asma en población general en España

Author

Blanco-Aparicio, Marina, García-Río, Francisco José, González-Barcala, Francisco Javier, Jiménez-Ruiz, Carlos A., Muñoz, Xavier, Plaza, Vicente, Soto-Campos, José Gregorio, Urrutia-Landa, Isabel, Almonacid, Carlos, Peces-Barba, Gregorio, and Álvarez-Gutiérrez, Francisco Javier

Published
2023
Full Text
View/download PDF

12. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

Author

Matabuena, Marcos, Salgado, Francisco Javier, Nieto-Fontarigo, Juan José, Álvarez-Puebla, María J., Arismendi, Ebymar, Barranco, Pilar, Bobolea, Irina, Caballero, María L., Cañas, José Antonio, Cárdaba, Blanca, Cruz, María Jesus, Curto, Elena, Domínguez-Ortega, Javier, Luna, Juan Alberto, Martínez-Rivera, Carlos, Mullol, Joaquim, Muñoz, Xavier, Rodriguez-Garcia, Javier, Olaguibel, José María, Picado, César, Plaza, Vicente, Quirce, Santiago, Rial, Manuel J., Romero-Mesones, Christian, Sastre, Beatriz, Soto-Retes, Lorena, Valero, Antonio, Valverde-Monge, Marcela, Del Pozo, Victoria, Sastre, Joaquín, and González-Barcala, Francisco Javier

Published
2023
Full Text
View/download PDF

14. Documento de consenso de asma grave en adultos. Actualización 2022

Author

Alvarez-Gutiérrez, Francisco Javier, Blanco-Aparicio, Marina, Casas-Maldonado, Francisco, Plaza, Vicente, González-Barcala, Francisco Javier, Carretero-Gracia, José Ángel, Castilla-Martínez, Manuel, Cisneros, Carolina, Diaz-Pérez, David, Domingo-Ribas, Christian, Martínez-Moragon, Eva, Muñoz, Xavier, Padilla-Galo, Alicia, Perpiñá-Tordera, Miguel, and Soto-Campos, Gregorio

Published
2022
Full Text
View/download PDF

15. Urinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers.

Author

Martelo-Vidal, Laura, Vázquez-Mera, Sara, Miguéns-Suárez, Pablo, Bravo-López, Susana Belén, Makrinioti, Heidi, Domínguez-Arca, Vicente, de-Miguel-Díez, Javier, Gómez-Carballa, Alberto, Salas, Antonio, González-Barcala, Francisco Javier, Salgado, Francisco Javier, and Nieto-Fontarigo, Juan José

Abstract

This study aims to develop a protocol for respiratory disease-associated biomarker discovery by combining urine proteome studies with urinary exosome components analysis (i.e., miRNAs). To achieve this, urine was DTT treated to decrease uromodulin, then concentrated and ultracentrifuged. Proteomic analyses of exosome-free urine were performed using LC-MS/MS. Simultaneously, miRNA expression from urine exosomes was measured using either RTqPCR (pre-amplification) or nCounter Nanostring (non-amplication) analyses. We detected 548 different proteins in exosome-free urine samples (N = 5) with high confidence (FDR < 1%), many of them being expressed in different non-renal tissues. Specifically, lung-related proteins were overrepresented (Fold enrichment = 1.31; FDR = 0.0335) compared to whole human proteome, and 10–15% were already described as protein biomarkers for several pulmonary diseases. Urine proteins identified belong to several functional categories important in respiratory pathology. We could confirm the expression of miRNAs previously connected to respiratory diseases (i.e., miR-16-5p, miR-21-5p, miR-146a-5p, and miR-215-5p) in urine exosomes by RTqPCR. Finally, we detected 333 miRNAs using Nanostring, 15 of them up-regulated in T2high asthma (N = 4) compared to T2low asthma (N = 4) and healthy subjects (N = 4). Therefore, this protocol combining the urinary proteome (exosome free) with the study of urinary exosome components (i.e., miRNAs) holds great potential for molecular biomarker discovery of non-renal and particularly respiratory pathologies. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

16. Exploring CD26−/lo subpopulations of lymphocytes in asthma phenotype and severity: A novel CD4+ T cell subset expressing archetypical granulocyte proteins.

Author

Vázquez‐Mera, Sara, Martelo‐Vidal, Laura, Miguéns‐Suárez, Pablo, Bravo, Susana Belén, Saavedra‐Nieves, Paula, Arias, Pilar, Ferreiro‐Posse, Antía, Vázquez‐Lago, Juan, Salgado, Francisco Javier, González‐Barcala, Francisco Javier, and Nieto‐Fontarigo, Juan José

Subjects
LYMPHOCYTE subsets, T cells, KILLER cells, EXTRACELLULAR matrix, EOSINOPHILS
Abstract

Background: Asthma pathology may induce changes in naïve/memory lymphocyte proportions assessable through the evaluation of surface CD26 (dipeptidyl peptidase 4/DPP4) levels. Our aim was to investigate the association of asthma phenotype/severity with the relative frequency of CD26−/lo, CD26int and CD26hi subsets within different lymphocyte populations. Methods: The proportion of CD26−/lo, CD26int and CD26hi subsets within CD4+ effector T cells (Teff), total CD4− lymphocytes, γδ‐T cells, NK cells and NKT cells was measured in peripheral blood samples from healthy (N = 30) and asthma (N = 119) donors with different phenotypes/severities by flow cytometry. We performed K‐means clustering analysis and further characterised the CD4+CD26−/lo Teff cell subset by LC–MS/MS and immunofluorescence. Results: Cluster analysis including clinical and flow cytometry data resulted in four groups, two of them with opposite inflammatory profiles (neutrophilic vs. eosinophilic). Neutrophilic asthma presented reduced CD4−CD26hi cells, which negatively correlated with systemic inflammation. Eosinophilic asthma displayed a general expansion of CD26−/lo subsets. Specifically, CD4+CD26−/lo Teff expansion was confirmed in asthma, especially in atopic patients. Proteomic characterisation of this subset with a TEM/TEMRA phenotype revealed upregulated levels of innate (e.g. MPO and RNASE2) and cytoskeleton/extracellular matrix (e.g. MMP9 and ACTN1) proteins. Immunofluorescence assays confirmed the presence of atypical proteins for CD4+ T cells, and an enrichment in 'flower‐like' nuclei and MMP9/RNASE2 levels in CD4+CD26−/lo Teff compared to CD4+ T lymphocytes. Conclusion: There is an association between CD26 levels in different lymphocyte subsets and asthma phenotype/severity. CD4+CD26−/loTEMRA cells expressing innate proteins specific to eosinophils/neutrophils could be determinant in sustaining long‐term inflammation in adult allergic asthma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Impact of anxiety and depression on the prognosis of copd exacerbations

Author

Martínez-Gestoso Sandra, García-Sanz María-Teresa, Carreira José-Martín, Salgado Francisco-Javier, Calvo-Álvarez Uxío, Doval-Oubiña Liliana, Camba-Matos Sandra, Peleteiro-Pedraza Lorena, González-Pérez Miguel-Angel, Penela-Penela Pedro, Vilas-Iglesias Andrés, and González-Barcala Francisco-Javier

Subjects
COPD, Anxiety, Depression, Prognosis, Diseases of the respiratory system, RC705-779
Abstract

Abstract Background Frequent and highly prevalent as comorbidities in Chronic Obstructive Pulmonary Disease (COPD) patients, both depression and anxiety seem to have an impact on COPD prognosis. However, they are underdiagnosed and rarely treated properly. Aim To establish the prevalence of depression and anxiety in patients admitted for Acute Exacerbation of COPD (AECOPD) and determine their influence on COPD prognosis. Methods Prospective observational study conducted from October 1, 2016 to October 1, 2018 at the following centers in Galicia, Spain: Salnés County Hospital, Arquitecto Marcide, and Clinic Hospital Complex of Santiago de Compostela. Patients admitted for AECOPD who agreed to participate and completed the anxiety and depression scale (HADS) were included in the study. Results 288 patients (46.8%) were included, mean age was 73.7 years (SD 10.9), 84.7% were male. 67.7% patients were diagnosed with probable depression, and depression was established in 41.7%; anxiety was probable in 68.2% and established in 35.4%. 60.4% of all patients showed symptoms of both anxiety and depression. Multivariate analysis relates established depression with a higher risk of late readmission (OR 2.06, 95% CI 1.28; 3.31) and a lower risk of mortality at 18 months (OR 0.57, 95% CI 0.37; 0.90). Conclusion The prevalence of anxiety and depression in COPD patients is high. Depression seems to be an independent factor for AECOPD, so early detection and a multidisciplinary approach could improve the prognosis of both entities. The study was approved by the Ethical Committee of Galicia (code 2016/460).

Published
2022
Full Text
View/download PDF

21. Health outcomes: Towards the accreditation of respiratory medicine departments

Author

Álvarez-Dobaño, José Manuel, Atienza, Gerardo, Zamarrón, Carlos, Toubes, María Elena, Ferreiro, Lucía, Riveiro, Vanessa, Casal, Ana, Suárez-Antelo, Juan, Rodríguez-Núñez, Nuria, Lama-López, Adriana, Rábade-Castedo, Carlos, Rodríguez-García, Carlota, Lourido-Cebreiro, Tamara, Ricoy, Jorge, Abelleira, Romina, Golpe, Antonio, Pais, Beatriz, González-Barcala, Francisco Javier, and Valdés, Luis

Published
2021
Full Text
View/download PDF

22. Efficacy of mepolizumab in usual clinical practice and characteristics of responders

Author

Rodríguez-García, Carlota, Blanco-Aparicio, Marina, Nieto-Fontarigo, Juan José, Blanco-Cid, Nagore, Gonzalez-Fernandez, Coral, Mosteiro-Añon, Mar, Calvo-Alvarez, Uxío, Perez-De-Llano, Luis, Corbacho-Abelaira, María Dolores, Lourido-Cebreiro, Tamara, Dominguez-Juncal, Luis Miguel, Crespo-Diz, Carlos, Dacal-Quintas, Raquel, Pallares-Sanmartin, Abel, Dacal-Rivas, David, and Gonzalez-Barcala, Francisco Javier

Published
2021
Full Text
View/download PDF

23. Resultados de salud: hacia la acreditación de los servicios de neumología

Author

Álvarez-Dobaño, José Manuel, Atienza, Gerardo, Zamarrón, Carlos, Toubes, María Elena, Ferreiro, Lucía, Riveiro, Vanessa, Casal, Ana, Suárez-Antelo, Juan, Rodríguez-Núñez, Nuria, Lama-López, Adriana, Rábade-Castedo, Carlos, Rodríguez-García, Carlota, Lourido-Cebreiro, Tamara, Ricoy, Jorge, Abelleira, Romina, Golpe, Antonio, Pais, Beatriz, González-Barcala, Francisco Javier, and Valdés, Luis

Published
2021
Full Text
View/download PDF

26. Contributors

Author

Abril, Ana G., primary, Agregán, Rubén, additional, Banerjee, Rituparna, additional, Barros-Velázquez, Jorge, additional, Biswas, Subhasish, additional, Bravo, S.B., additional, Calo-Mata, Pilar, additional, Carrera, Mónica, additional, Chantada-Vázquez, M.D.P., additional, Dhanapal, Anand Raj, additional, Dominguez, Ruben, additional, Echegaray, Noemí, additional, Fedoseeva, Natalya, additional, Franco Ruiz, Daniel, additional, Gagaoua, Mohammed, additional, González-Barcala, Francisco Javier, additional, López Pedrouso, María, additional, Lorenzo, Jose M., additional, Maheswarappa, Naveena Basappa, additional, Mohan, Kiran, additional, Munekata, Paulo E.S., additional, Nieto-Fontarigo, Juan José, additional, Núñez, C., additional, Pateiro, Mirian, additional, Rebezov, Maksim, additional, Salgado Castro, Francisco Javier, additional, Schilling, M. Wes, additional, Sentandreu, Enrique, additional, Sentandreu, Miguel Ángel, additional, Shariati, Mohammad Ali, additional, Stryiński, Robert, additional, Suman, Surendranath, additional, Thiruvengadam, Muthu, additional, Venkidasamy, Baskar, additional, Villa, Tomás G., additional, Zamuz, Sol, additional, Zhang, Xue, additional, Zhu, Yao, additional, and Łopieńska-Biernat, Elżbieta, additional

Published
2022
Full Text
View/download PDF

28. Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial

Author

Castro, Mario, primary, Papi, Alberto, additional, Porsbjerg, Celeste, additional, Lugogo, Njira, additional, Brightling, Christopher, additional, González-Barcala, Francisco-Javier, additional, Bourdin, Arnaud, additional, Ostrovskyy, Mykola, additional, Staevska, Maria, additional, Chou, Pai-Chen, additional, Duca, Liliana, additional, Pereria, Ana, additional, Fogarty, Charles, additional, Nadama, Rufai, additional, Zhang, Mei, additional, Rodrigues, Amelie, additional, Soler, Xavier, additional, Pantelimon, Simona, additional, Sacks, Harry, additional, Deniz, Yamo, additional, Rowe, Paul, additional, De Prado Gomez, Lucia, additional, and Jacob-Nara, Juby, additional

Published
2024
Full Text
View/download PDF

32. COMPARISON OF LONG-TERM RESPONSE AND REMISSION TO OMALIZUMAB AND ANTI-IL5/IL5R USING DIFFERENT CRITERIA IN A REAL-LIFE COHORT OF SEVERE ASTHMA PATIENTS

Author

Valverde-Monge, Marcela, primary, Sánchez-Carrasco, Patricia, additional, Betancor, Diana, additional, Barroso, Blanca, additional, Manuel Rodrigo-Muñoz, José, additional, Mahillo-Fernández, Ignacio, additional, Arismendi, Ebymar, additional, Bobolea, Irina, additional, Cárdaba, Blanca, additional, Cruz, María Jesús, additional, Pozo, Victoria Del, additional, Domínguez-Ortega, Javier, additional, González-Barcala, Francisco Javier, additional, María Olaguibel, José, additional, Luna-Porta, JA, additional, Martínez-Rivera, Carlos, additional, Mullol, Joaquim, additional, Muñoz, Xavier, additional, Peleteiro-Pedraza, Lorena, additional, Valles, Cesar Picado, additional, Plaza, Vicente, additional, Quirce, Santiago, additional, Rial, Manuel Jorge, additional, Soto-Retes, Lorena, additional, Valero, Antonio, additional, and Sastre, Joaquín, additional

Published
2023
Full Text
View/download PDF

33. The MEGA Project: A Study of the Mechanisms Involved in the Genesis and Disease Course of Asthma. Asthma Cohort Creation and Long-Term Follow-Up

Author

Muñoz, Xavier, Álvarez-Puebla, María José, Arismendi, Ebymar, Arochena, Lourdes, del Pilar Ausín, María, Barranco, Pilar, Bobolea, Irina, Cañas, Jose Antonio, Cardaba, Blanca, Crespo, Astrid, del Pozo, Victora, Domínguez-Ortega, Javier, del Mar Fernandez-Nieto, María, Giner, Jordi, González-Barcala, Francisco Javier, Luna, Juan Alberto, Mullol, Joaquim, Ojanguren, Iñigo, Olaguibel, José María, Picado, César, Plaza, Vicente, Quirce, Santiago, Ramos, David, Rial, Manuel, Romero-Mesones, Christian, Salgado, Francisco Javier, San-José, María Esther, Sánchez-Diez, Silvia, Sastre, Beatriz, Sastre, Joaquin, Soto, Lorena, Torrejón, Montserrat, Urnadoz, Marisa, Valdes, Luis, Valero, Antonio, and Cruz, María Jesús

Published
2018
Full Text
View/download PDF

35. Estudio de los mecanismos implicados en la génesis y evolución del asma (proyecto MEGA): creación y seguimiento a largo plazo de una cohorte de pacientes asmáticos

Author

Muñoz, Xavier, Álvarez-Puebla, María José, Arismendi, Ebymar, Arochena, Lourdes, Ausín, María del Pilar, Barranco, Pilar, Bobolea, Irina, Cañas, Jose Antonio, Cardaba, Blanca, Crespo, Astrid, del Pozo, Victora, Domínguez-Ortega, Javier, Fernandez-Nieto, María del Mar, Giner, Jordi, González-Barcala, Francisco Javier, Luna, Juan Alberto, Mullol, Joaquim, Ojanguren, Iñigo, Olaguibel, José María, Picado, César, Plaza, Vicente, Quirce, Santiago, Ramos, David, Rial, Manuel, Romero-Mesones, Christian, Salgado, Francisco Javier, San-José, María Esther, Sánchez-Diez, Silvia, Sastre, Beatriz, Sastre, Joaquin, Soto, Lorena, Torrejón, Montserrat, Urnadoz, Marisa, Valdes, Luis, Valero, Antonio, and Cruz, María Jesús

Published
2018
Full Text
View/download PDF

36. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria

Author

Olaguibel, José María, Rodrigo-Muñoz, José Manuel, Puebla, Maria Jose Alvarez, Arismendi, Ebymar, Bobolea, Irina, Cárdaba, Blanca, Cruz, María Jesús, Curto, Elena, Del Pozo, Victoria, Domínguez-Orteg, Javier, González-Barcala, Francisco-Javier, Luna-Porta, J.A., Martínez-Rivera, Carlos, Mullol, Joaquim, Muñoz, Xavier, Picado, Cesar, Plaza, Vicente, Quirce, Santiago, Rial, Manuel Jorge, Soto-Retes, Lorena, Valero, Antonio, Betancor, Diana, Barroso, Blanca, Valverde-Monge, Marcela, Gomez-Lopez, Alicia, and Sastre, Joaquin

Published
2024
Full Text
View/download PDF

38. Stress urinary incontinence in women with chronic cough: impact on cough-related quality of life

Author

Puente-Maestu, Luis, primary, Quirce, Santiago, additional, Dávila, Ignacio, additional, Arismendi, Ebymar, additional, Martínez-Moragón, Eva, additional, Sola-Martínez, Javier, additional, De Diego, Alfredo, additional, González-Barcala, Francisco Javier, additional, Cea-Calvo, Luis, additional, Rivas-Pardinas, Cristina, additional, Sanchez Jareño, Marta, additional, and Domingo-Ribas, Christian, additional

Published
2023
Full Text
View/download PDF

39. Mepolizumab alters the phenotype and activation status of peripheral blood eosinophils in patients with severe eosinophilic asthma

Author

Miguéns-Suárez, Pablo, primary, Vázquez-Mera, Sara, additional, Martelo-Vidal, Laura, additional, Calvo-Álvarez, Uxío, additional, Ruiz-Ferreras, Raquel, additional, Blanco-Aparicio, Marina, additional, González-Fernández, Coral, additional, Mosteiro-Añón, Mar, additional, Corbacho-Abelaira, María Dolores, additional, Méndez-Brea, Paula, additional, Nieto-Fontarigo, Juan José, additional, Salgado, Francisco Javier, additional, and González-Barcala, Francisco Javier, additional

Published
2023
Full Text
View/download PDF

40. Prognostic Usefulness Of Basic Analytical Data In Chronic Obstructive Pulmonary Disease Exacerbation

Author

Gestoso, Sandra Martínez, primary, García-Sanz, María-Teresa, additional, Carreira, José-Martín, additional, Nieto-Fontarigo, Juan-José, additional, Álvarez, Uxío Calvo, additional, Oubiña, Liliana Doval, additional, Matos, Sandra Camba, additional, Pedraza, Lorena Peleteiro, additional, Veiga, Iria Roibás, additional, and González-Barcala, Francisco-Javier, additional

Published
2023
Full Text
View/download PDF

41. Burden of refractory and unexplained chronic cough on patients’ lives: a cohort study

Author

Puente-Maestu, Luis, primary, Dávila, Ignacio, additional, Quirce, Santiago, additional, Crespo-Lessmann, Astrid, additional, Martínez-Moragón, Eva, additional, Sola, Javier, additional, Nieto, María Luisa, additional, González-Barcala, Francisco Javier, additional, Cea-Calvo, Luis, additional, Sánchez-Jareño, Marta, additional, Rivas-Pardinas, Cristina, additional, and Domingo, Christian, additional

Published
2023
Full Text
View/download PDF

42. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

Author

Betancor, Diana, primary, Villalobos-Vilda, Carlos, additional, Olaguibel, José María, additional, Rodrigo-Muñoz, José Manuel, additional, Puebla, María Jose Alvarez, additional, Arismendi, Ebymar, additional, Barranco, Pilar, additional, Barroso, Blanca, additional, Bobolea, Irina, additional, Cárdaba, Blanca, additional, Cruz, María Jesús, additional, Curto, Elena, additional, Pozo, Victoria Del, additional, Domínguez-Ortega, Javier, additional, González-Barcala, Francisco-Javier, additional, Luna-Porta, Juan Alberto, additional, Martínez-Rivera, Carlos, additional, Mullol, Joaquim, additional, Muñoz, Xavier, additional, Picado, Cesar, additional, Plaza, Vicente, additional, Quirce, Santiago, additional, Rial, Manuel Jorge, additional, Soto-Retes, Lorena, additional, Valero, Antonio, additional, Valverde-Monge, Marcela, additional, and Sastre, Joaquín, additional

Published
2023
Full Text
View/download PDF

48. Eficacia a longo prazo da triple terapia no asma. Estudo no mundo real

Author

González Barcala, Francisco Javier (dir.), Pérez de Llano, Luis Alejandro, Universidade de Santiago de Compostela. Facultade de Medicina e Odontoloxía, Pérez Ortiz, Daniel, González Barcala, Francisco Javier (dir.), Pérez de Llano, Luis Alejandro, Universidade de Santiago de Compostela. Facultade de Medicina e Odontoloxía, and Pérez Ortiz, Daniel

Abstract

La triple terapia del asma (TT) consiste en la combinación de tres medicamentos inhalados diferentes para el tratamiento de esta enfermedad respiratoria crónica. Estos medicamentos incluyen un corticosteroide inhalado (CI), un beta-agonista de larga duración (LABA) y un anticolinérgico de acción prolongada (LAMA). Cada uno de estos medicamentos tiene un mecanismo de acción único y actúa de manera complementaria para controlar los síntomas y mejorar la función pulmonar en pacientes con asma no controlada. La TT ha demostrado ser más efectiva que el tratamiento convencional (combinación CI/LABA) en algunas situaciones clínicas. Diversos estudios han mostrado que los pacientes que reciben TT experimentan una mejoría significativa en la función pulmonar, una disminución en las exacerbaciones, en la frecuencia y gravedad de los síntomas y una reducción en el uso de medicación de rescate respecto a la combinación CI/LABA. El objetivo de este estudio es examinar, en un contexto de “vida real” la efectividad de la TT en asma, evaluando en qué medida previene la escalada terapéutica a largo plazo, su impacto en las diferentes variables que definen el control de la enfermedad y analizando qué factores predicen una mejor o peor respuesta a este tratamiento. Para ello se realiza un estudio retrospectivo y multicéntrico con un seguimiento de varias visitas (6 meses, 12 meses y largo plazo). Se incluyeron 197 pacientes, con un seguimiento medio de 50 meses. Sólo el 12,5% precisaron una escalada terapéutica a lo largo del estudio y el 57% estaban controlados al final del seguimiento. Valores más bajos del ACT, mayor frecuencia de exacerbaciones antes de iniciar la TT y la coexistencia de bronquiectasias fueron predictores de peor respuesta, A terapia triple do asma (TT) consiste na combinación de tres medicamentos inhalados diferentes para o tratamento desta enfermidade respiratoria crónica. Estes medicamentos inclúen un corticosteroide inhalado (CI), un beta-agonista de longa duración (LABA) e un anticolinérgico de acción prolongada (LAMA). Cada un destes medicamentos ten un mecanismo de acción único e actúa de maneira complementaria para controlar os síntomas e mellorar a función pulmonar en pacientes con asma non controlada. A TT demostrou ser máis efectiva que o tratamento convencional (combinación CI/LABA) en algunhas situacións clínicas. Estudos clínicos mostraron que os pacientes que reciben TT experimentan unha melloría significativa na función pulmonar, unha diminución nas exacerbacións, na frecuencia e gravidade dos síntomas e unha redución no uso de medicación de rescate. O obxectivo deste estudo é examinar, nun contexto de "vida real", a efectividade da TT no asma, avaliando en qué medida prevén a escalada terapéutica a longo prazo, o seu impacto nas diferentes variables que definen o control da enfermidade e analizando que factores predicen unha mellor ou peor resposta a este tratamento. Para iso, realízase un estudo retrospectivo e multicéntrico cun seguimento de varias visitas (6 meses, 12 meses e a longo prazo). Incluíronse 197 pacientes, cun seguimento medio de 50 meses. Só o 12,5% precisaron unha escalada terapéutica ao longo do estudo e o 57% estaban controlados ao final do seguimento. Valores máis baixos do ACT, maior frecuencia de exacerbacións antes de iniciar a TT e a coexistencia de bronquiectasias foron predictores de peor resposta, Triple therapy for asthma (TT) refers to the combination of three different medications used in the treatment of this chronic respiratory disease. These medications include an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting anticholinergic (LAMA). Each of these medications has a unique mechanism of action and acts in a complementary manner to control symptoms and improve lung function in patients with uncontrolled asthma. Triple therapy has been shown to be more effective than conventional treatment (ICS/LABA combination) in asthma control. Clinical studies have demonstrated that patients receiving TT treatment, have more significant improvement in lung function, a decrease in exacerbations, frequency and severity of symptoms, and a reduction in the use of rescue medication. The objective of this study is to examine the effectiveness of TT in asthma in a real-life context, assessing to what extent it prevents long-term therapeutic escalation, its impact on different variables defining disease control, and analyzing which factors predict a better or worse response to this treatment. For this purpose, a retrospective and multicenter study is being conducted with multiple follow-up visits (6 months, 12months, and long-term). A total of 197 patients were included, with an average follow-up of 50 months. Only 12.5% required therapeutic escalation during the study, and 57% were controlled at the end of the follow-up. Lower ACT scores, higher exacerbation rates prior to initiating TT, and the coexistence of bronchiectasis were predictors of treatment failure

Published
2023

49. Outpatient atorvastatin use and severe COVID‐19 outcomes: A population‐based study

Author

Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina, Visos‐Varela, Irene, Zapata‐Cachafeiro, Maruxa, Pintos‐Rodríguez, Samuel, Bugarín‐González, Rosendo, González Barcala, Francisco Javier, Herdeiro, Maria T., Piñeiro‐Lamas, María, Figueiras Guzmán, Adolfo, Salgado-Barreira, Ángel, Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina, Visos‐Varela, Irene, Zapata‐Cachafeiro, Maruxa, Pintos‐Rodríguez, Samuel, Bugarín‐González, Rosendo, González Barcala, Francisco Javier, Herdeiro, Maria T., Piñeiro‐Lamas, María, Figueiras Guzmán, Adolfo, and Salgado-Barreira, Ángel

Abstract

Evidence of the effect of statins on patients with coronavirus disease (2019) COVID-19 is inconsistent. The aim of this study was to evaluate the association between chronic use of statins—both overall and by active ingredient—and severe outcomes of COVID-19 (risk of hospitalization and mortality), progression to severe outcomes, and susceptibility to the virus. We conducted a population-based case–control study with data from electronic records to assess the risk of (1) hospitalization: cases were patients admitted due to COVID-19 and controls were subjects without COVID-19; (2) mortality: cases were hospitalized patients who died due to COVID-19 and controls were subjects without COVID-19; (3) progression: cases were hospitalized COVID-19 subjects and controls were nonhospitalized COVID-19 patients; and (4) susceptibility: cases were patients with COVID-19 (both hospitalized and nonhospitalized) and controls were subjects without COVID-19. We collected data on 2821 hospitalized cases, 26 996 nonhospitalized cases, and 52 318 controls. Chronic use of atorvastatin was associated with a decreased risk of hospitalization (adjusted odds ratios [aOR] = 0.83; 95% confidence interval [CI]: 0.74–0.92) and mortality (aOR = 0.70; 95% CI: 0.53–0.93), attributable in part to a lower risk of susceptibility to the virus (aOR = 0.91; 95% CI: 0.86–0.96). Simvastatin was associated with a reduced risk of mortality (aOR = 0.59; 95% CI: 0.40–0.87). The wide degree of heterogeneity observed in the estimated odds ratios (ORs) of the different statins suggests that there is no class effect. The results of this real-world study suggest that chronic use of atorvastatin (and to a lesser degree, of simvastatin) is associated with a decrease in risk of severe COVID-19 outcomes

Published
2023

50. Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life.

Author

Arismendi, Ebymar, Puente-Maestu, Luis, Domingo, Christian, Dávila, Ignacio, Quirce, Santiago, González-Barcala, Francisco Javier, Crespo-Lessmann, Astrid, Sánchez-Jareño, Marta, Rivas-Pardinas, Cristina, and Cea-Calvo, Luis

Abstract

Background: Stress urinary incontinence (SUI) is common in women with chronic cough but may be overlooked. Objective: To determine the frequency of underdiagnosis of cough-related SUI and its impact on women's general health status and quality of life (QoL). Methods: Data were analyzed for 147 women with refractory/unexplained chronic cough. Relevant details were collected from clinical charts and a patient-completed survey. General health status was assessed using the EuroQoL visual analogue scale (EQ-VAS) and QoL with the cough-specific Leicester Cough Questionnaire (LCQ). Results: Women were classified into diagnosed (n = 32; 21.8%) or undiagnosed (n = 33; 22.4%) cough-related SUI, and no SUI (n = 82; 55.6%) groups. Women with versus without cough-related SUI perceived poorer health status and greater impact of cough on everyday lives. Mean LCQ scores were significantly lower in cough-related SUI groups versus no SUI group. In multivariate analysis, the presence of cough-related SUI was significantly associated with lower EQ-VAS and LCQ scores. Conclusion: In our cohort, 44% of women had cough-related SUI, and half were undiagnosed. Irrespective of diagnosis, impairment to everyday lives and QoL was similar. Diagnosing cough-related SUI may identify additional patients who can benefit from therapies to suppress cough and improve QoL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results